Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| C4 Therapeutics, Inc.CCCC · Entity 5503 | VP of Finance Corp Controller | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
C4 Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.54 · Expires 2031-02-10 | Direct | 23,100 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 23,100 · Balance 23,100 F1: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2021 Filed Feb 16, 2021 21:16 UTC | C4 Therapeutics, Inc. CCCC · Entity 5503 | GrantStock Option (Right to Buy) · Derivative | 23,100 | $0.00 Strike: $45.54 | $0.00 |
DisclosureSEC source: 0001209191-21-010711 · doc4.xml · derivative · entry 1 Wahlberg Laura Jean · CIK 0001825153 · VP of Finance Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,100 Underlying: Common Stock · 23,100 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments, with the first installment vesting on May 11, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.